- 35-1300Z - Invitrogen Antibodies MMP2 antibody

Submitted references MUC 15 Promotes Osteosarcoma Cell Proliferation, Migration and Invasion through Livin, MMP-2/MMP-9 and Wnt/β-Catenin Signal Pathway.

Chen T, Chen Z, Lian X, Wu W, Chu L, Zhang S, Wang L
Journal of Cancer 2021;12(2):467-473

Claudin-6 enhances cell invasiveness through claudin-1 in AGS human adenocarcinoma gastric cancer cells.

Torres-Martínez AC, Gallardo-Vera JF, Lara-Holguin AN, Montaño LF, Rendón-Huerta EP
Experimental cell research 2017 Jan 1;350(1):226-235

Possible Mechanisms of Di(2-ethylhexyl) Phthalate-Induced MMP-2 and MMP-9 Expression in A7r5 Rat Vascular Smooth Muscle Cells.

Shih MF, Pan KH, Cherng JY
International journal of molecular sciences 2015 Dec 4;16(12):28800-11

Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules.

Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T, Ajarim D, Adra C
PloS one 2011;6(11):e27339

MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression.

Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY, Zhuang SM
Hepatology (Baltimore, Md.) 2011 Nov;54(5):1729-40

A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.

Liu H, Chen A, Guo F, Yuan L
Cancer letters 2010 Sep 1;295(1):27-37

Influence of osteopontin short hairpin RNA on the proliferation and invasion of human renal cancer cells.

Liu H, Chen A, Guo F, Yuan L
Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 2010 Feb;30(1):61-8

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemistry analysis of MMP-2/CLG4A showing staining in the cytoplasm of paraffin-embedded human breast carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10 mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with MMP-2/CLG4A monoclonal antibody (Product # 35-1300Z) diluted in 3% BSA-PBS at a dilution of 1:20 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using a HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 ( a ) Effects of DEHP on MMP-2 and MMP-9 protein expression. VSMC ( n >= 3) were treated with DEHP (concentrations between 2 and 17.5 ppm) for 24 h prior to MMP-2 and MMP-9 protein extraction and expression. Statistics are shown for DEHP-treated cells * p < 0.05 and *** p < 0.005, compared to the respective controls; ( b ) Effects of DEHP on MMP-2 activity. VSMC were treated ( n >= 8) with DEHP (concentrations between 2 and 17.5 ppm) for 24 h prior to MMP-2 activities being measured. Statistics are shown for DEHP-treated cells *** p < 0.005, compared to the control; and ( c ) Effects of DEHP on MMP-9 activity. VSMC were treated ( n >= 8) with DEHP (concentrations between 2 and 17.5 ppm) for 24 h prior to MMP-9 activities being measured. Statistics are shown for DEHP-treated cells *** p < 0.005, compared to the control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 ( a ) Effects of p38 MAPK, ERK1/2, Akt, and NF-kappaB inhibitors on DEHP-induced MMP-2 expression. VSMC ( n >= 3) were pre-treated with SB203580 (10 uM), UO126 (10 uM), SH-5 (10 uM), and Helenalin (10 uM) for 2 h, DEHP (concentrations between 2 and 17.5 ppm) was then added and incubated for further 24 h prior to protein extraction. MMP-2 was expressed by Western blotting; and ( b ) effects of p38 MAPK, ERK1/2, Akt, and NF-kappaB inhibitors on DEHP-induced MMP-2 activity. VSMC ( n >= 3) were pre-treated with SB203580 (10 uM), UO126 (10 uM), SH-5 (10 uM), and Helenalin (10 uM) for 2 h, DEHP (7 or 10.5 ppm) was then added and incubated for further 24 h prior to MMP-2 activity being measured. Statistics are shown for all inhibitors-treated cells * p < 0.05, ** p < 0.01, and *** p < 0.005, compared to the DEHP-treated group.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Mechanisms of MUC15 on osteosarcoma proliferation, migration and invasion. Western blot detected the apoptosis-inhibiting protein Livin ( A ), the migration-related proteins MMP-9 /MMP-2 ( B ), EMT related proteins ( C ) and the Wnt/b-Catenin signaling pathway of OS cell ( D ).

35-1300Z

Antibody data